ÇмúÇà»ç
Korean Society of Gastrointestinal Cancer Research
Korean Society of Gastrointestinal Cancer Research
¼¼Á¾´ëÇб³ ÄÁº¥¼Ç¼¾ÅÍ ÄÁº¥¼ÇȦ 2022-06-17
Session I | Mini-review of ASCO/ESMO GI Cancer Symposium (What's new in 2022) | ÁÂÀå: ±èÈ£°¢(´ë±¸°¡Å縯ÀÇ´ë), ÀÓÀ±Á¤(µ¿±¹ÀÇ´ë) |
09:10-09:30 | 1. Esophageal/stomach cancer | À̹®¿ø(ºÎ»êÀÇ´ë) |
09:30-09:50 | 2. Colorectal cancer | ±è¼ºÁß(Á¶¼±ÀÇ´ë) |
09:50-10:10 | 3. Pancreatobiliary cancer | ¾Èµ¿¿ø(¼¿ïÀÇ´ë º¸¶ó¸Åº´¿ø) |
Session II | IASGO joint session : debate or controversial issues of GI cancer (English) | ÁÂÀå: ¼Û½Ã¿µ(¿¬¼¼ÀÇ´ë), Kyoichi Takaori(Kyoto university) |
10:40-11:05 | 1. Treatment of Obstructive Gastric Cancer with distant metastasis; Palliative Chemotherapy | ±è¼ºÀº(°í½ÅÀÇ´ë) |
11:05-11:30 | 2. Surgical Strategy for Stage IV Gastric Cancer; Neoadjuvant Chemotherapy followed by Curative Gastrectomy | Sang Woong Lee(Osaka Medical and Pharmaceutical University) |
11:30-11:55 | 3. Multi-modality treatment for oligometastatic pancreatic cancer : Surgical and local therapeutic concept from surgeon's view point | Masayuki Sho (Nara Medical University) |
11:55-12:20 | 4. Multi-modality treatment for oligometastatic pancreatic cancer : Conventional chemotherapy and immunotherapy from physician's view point | Á¶Àη¡(¼¿ïÀÇ´ë) |
Session III | Genomics and clinical application in GI cancers | ÁÂÀå: ±è¼º¼ö(°¡Å縯ÀÇ´ë), ¹æ½Â¹Î(¿¬¼¼ÀÇ´ë) |
13:20-13:45 | 1. Interpretation and clinical application of NGS(next generation sequencing) in GI cancer | ¹Ú¼º¿(GENOME INSIGHT Inc) |
13:45-14:10 | 2. Practical implications of the molecular and immunologic classifications in colorectal cancer | ¹èÁ¤¸ð(¼¿ïÀÇ´ë º´¸®°ú) |
14:10-14:35 | 3. Understanding and therapeutic application of glutamine metabolism in pancreatic cancer | ÇÑÁ¤¹Î(¿¬¼¼´ë ¾àÇдëÇÐ) |
14:35-15:00 | 4. Understanding subtype plasticity in pancreatic cancer | ³ëÀç¼®(¿¬¼¼´ë »ýÈÇаú) |
Session IV | Controversies and advance in the management of non-metastatic pancreatobiliary cancer | ÁÂÀå: ȲÁøÇõ(¼¿ïÀÇ´ë), ¹Úº´±Ô(±¹¹Î°Ç°º¸ÇèÀϻ꺴¿ø) |
15:20-15:45 | 1. Neoadjuvant therapy for resectable/borderline resectable pancreatic cancer | Á¶ÁßÇö(¿¬¼¼ÀÇ´ë) |
15:45-16:10 | 2. Optimal treatment sequencing for Locally advanced pancreatic cancer | À̵¿¿í(°æºÏÀÇ´ë) |
16:10-16:35 | 3. Neoadjuvant/adjuvant therapy for biliary tract cancer | ±èÀçȯ(¼¿ïÀÇ´ë) |
16:35-17:00 | 4. Novel radiation strategies for pancreatobiliary cancer | ÀÌÀÍÀç(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú) |
Session I | Free paper session | ÁÂÀå: À̼öÅÃ(ÀüºÏÀÇ´ë), ÀÌ»óÇù(¼¿ïÀÇ´ë) |
09:10-09:20 | Usefulness of in-stent radiofrequency ablation after occlusion of self-expandable metal stent in unresectable malignant biliary obstruction: Multicenter propensity-score matched study | ¹Ú³²¿µ(°æÈñÀÇ´ë) |
09:20-09:30 | ÅëÇÕÀû ´ÜÀÏ ¼¼Æ÷ Àü»çü ºÐ¼®À» ÅëÇÏ¿© È®ÀÎµÈ ÃéÀå¾Ï ¼¼Æ÷ÀÇ ºÐÀÚ»ý¹°ÇÐÀû ¾ÆÇüÀÇ µ¿Àû ÀüÀÌ | ÀÓ°¡¶÷(¿¬¼¼ÀÇ´ë) |
09:30-09:40 | ÃéÀå¾Ï Áø´Ü ÀÌÀü¿¡ ½ÃÇàµÈ CT ¿µ»ó¿¡¼ ÈÄÇâÀûÀ¸·Î °üÂûµÈ ÃéÀå¾Ï ÀÇ½É ¼Ò°ß | °íÈñµ¿(±¹¹Î°Ç°º¸Çè Àϻ꺴¿ø) |
09:40-09:50 | Incidence and risk factors of pancreatic cancer in patients with definite chronic pancreatitis: a multicenter retrospective study | ±èÇý¸²(°¡Å縯ÀÇ´ë) |
09:50-10:00 | Risk factors of short safety margin after endoscopic submucosal dissection for early gastric cancer | °¼±Çü(Ãæ³²ÀÇ´ë) |
10:00-10:10 | Endoscopic submucosal dissection using a detachable assistant robot: a comparative in vivo feasibility study | ±è»óÇö(°í·ÁÀÇ´ë) |
10:10-10:20 | Comparison of clinical outcomes: stenting as bridge to surgery versus surgery alone in colorectal cancer obstruction | È«½Â¹Î(ºÎ»êÀÇ´ë) |
Session II | New diagnostic paradigm in GI disease (Combined session of KSGC, KCHUGR, KSNM) | ÁÂÀå: ÀüÈÆÀç(°í·ÁÀÇ´ë), Á¤´ë¿µ(°¡Å縯ÀÇ´ë)) |
10:40-11:05 | Updated diagnostic methodology in GI motility disorder | Á¤±â¿í(¿ï»êÀÇ´ë) |
11:05-11:30 | Application of AI in endoscopy for GI cancer | ¹æâ¼®(ÇѸ²ÀÇ´ë) |
11:30-11:55 | Application of AI in pathology for GI cancer | ÀÌ°æºÐ(¼¿ïÀÇ´ë º´¸®°ú) |
11:55-12:20 | Application of AI in radiology for GI cancer | ±è³²±¹(¿ï»êÀÇ´ë À¶ÇÕÀÇÇаú) |
Session III | Plenary session | ÁÂÀå: ¹Ú¼±ÀÚ(°í½ÅÀÇ´ë), ¹ÚÁ¤¿±(¿¬¼¼ÀÇ´ë) |
13:20-13:32 | Outcomes of Palliative Chemotherapy for Ampulla of Vater Adenocarcinoma: A Korean Multicenter Study | ±è¼ÒÁ¤(¿¬¼¼ÀÇ´ë) |
13:32-13:44 | Associated factors of gastric and duodenal neuroendocrine neoplasms: a multicenter casecontrol study | ³²±¤¿ì(´Ü±¹ÀÇ´ë) |
13:44-13:56 | Long-term Outcomes of Endoscopic Papillectomy for Ampullary High-grade Dysplasia or Earlystage Cancer: a Multicenter Retrospective Cohort Study in Korea | À±½Â¹è(°¡Å縯ÀÇ´ë) |
13:56-14:09 | High expression of latexin can be a novel prognostic marker for pancreatic cancer | ¹ÚÂùÈñ(¿¬¼¼ÀÇ´ë) |
14:09-14:22 | Single Cell RNA Sequencing Analysis and its Clinical Significance in Pancreatic Ductal Adenocarcinoma (PDAC) | ±èÇý¹Î(¼º±Õ°üÀÇ´ë) |
14:22-14:35 | Analysis of risk factors for recurrence of distal bile duct cancer without lymph node metastasis after curative resection: Is adjuvant therapy really required? | ±è¼ÒÁ¤(¿¬¼¼ÀÇ´ë) |
14:35-14:48 | Comparison of the Quantity and Size Distribution between Normal Cell Free DNA and Circulating Tumor DNA in Korean Colorectal Cancer Patients | ±è»óÇö(°í·ÁÀÇ´ë) |
14:48-15:00 | Identification and Analysis of Circulating MicroRNAs expression profiles in XELOX Chemotherapy-induced Peripheral Neuropathy of Patients with Gastric Cancer | ±èµ¿¿í(ºÎ»êÀÇ´ë) |
Session IV | Clinical advice needed in difficult situations of gastrointestinal cancer | ÁÂÀå: ÁøÀ±ÅÂ(°í·ÁÀÇ´ë), ±èÇö¼ö(Àü³²ÀÇ´ë) |
15:20-15:45 | 1. Peritoneal carcinomatosis: Cytoreductive surgery vs. HIPEC vs. PIPAC | ¹é½ÂÇõ(¿¬¼¼ÀÇ´ë ´ëÀåÇ×¹®¿Ü°ú) |
15:45-16:10 | 2. Malignant colorectal obstruction: surgery vs. stent | ±èÁ¤È£(°¡ÃµÀÇ´ë) |
16:10-16:35 | 3. Overcoming chemo-resistance in gastric cancer | ¹®Èñ¼®(Ãæ³²ÀÇ´ë) |
16:35-17:00 | 4. Endotherapy for cancer bleeding and post-operative complications | Á¶¿µ½Å(¼øõÇâÀÇ´ë) |